Apnimed's financials show a transition from R&D to pre-commercial buildout, with a strong cash position and multiple years of ...
Our current projection also is a (conservative?) 20% chance that 2026 fails to reach 1982’s 17.4 ACE and becomes the quietest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results